Zai Lab Limited Unsponsored ADR ZLAB
24.98
(0.30)
(1.19%)
as of 25 Sep
- Market cap
- $2.9B
- P/E
- 0.0×
Follow ZLAB
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
8.46 | 4.20 | 4.60 | 4.72 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(116.56) | (74.25) | (174.87) | (33.47) | |
P/B ratio |
4.91 | 2.70 | 3.15 | 3.50 | |
Price to Tangible BV |
5.32 | 3.04 | 3.57 | 4.09 | |
EV/Sales |
7.07 | 2.93 | 3.39 | 3.65 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(17.29) | (8.93) | (15.20) | (12.32) | |
EV/FCF |
(14.84) | (8.21) | (11.57) | (10.11) | |
Quick Ratio |
2.51 | 2.15 | 2.07 | 1.84 | |
Current Ratio |
2.87 | 2.45 | 2.40 | 2.13 | |
Net Debt/EBITDA |
13.28 | 8.75 | 8.19 | 6.50 | |
Debt/Assets |
17.52% | 17.45% | 19.51% | 22.15% | |
Debt/Equity |
0.27 | 0.29 | 0.32 | 0.39 | |
Asset Turnover |
0.41 | 0.39 | 0.40 | 0.40 | |
Operating CF/Net income |
0.89 | 0.52 | 0.23 | 1.25 | |
Capex/Depreciation |
(1.57) | (0.50) | (8.74) | (0.52) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
41.28% | 48.30% | 65.85% | 58.10% | |
Selling, General and Administrative Expense of Revenue |
60.39% | 57.24% | 65.32% | 68.55% | |
Intangible Assets out of Total Assets |
0.05 | 0.07 | 0.07 | 0.08 | |
Share Based Compensation of Revenue |
14.58% | 12.46% | 13.58% | 11.23% | |
Graham Net Nets |
0.17 | 0.29 | 0.25 | 0.21 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(5.75%) | (9.13%) | (8.61%) | (9.00%) | |
Free Cash Flow Yield |
(5.63%) | (8.49%) | (6.37%) | (7.65%) | |
Revenue per Share |
1.05 | 1.16 | 0.90 | 0.95 | |
Operating CF per Share |
(0.29) | (0.24) | (0.11) | (0.57) | |
Capex per Share |
(0.04) | (0.01) | (0.20) | (0.01) | |
Free Cash Flow per Share |
(0.33) | (0.25) | (0.31) | (0.58) | |
Cash per Share |
7.41 | 7.21 | 6.87 | 6.42 | |
Shareholders Equity per Share |
6.90 | 6.53 | 5.98 | 5.43 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.90 | 6.53 | 5.98 | 5.43 | |
Free Cash Flow |
(36.09) | (27.32) | (34.20) | (64.82) | |
Working Capital |
673.18 | 603.12 | 551.75 | 485.45 | |
Capital Expenditures |
(4.05) | (1.30) | (22.29) | (1.42) | |
Net Current Asset Value |
633.95 | 562.40 | 510.97 | 446.28 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.01 | 0.22 | 0.01 | |
Net Profit Margin |
(30.98%) | (39.51%) | (51.22%) | (47.81%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
67.67 | 95.65 | 65.31 | 79.05 | |
Average Payables |
110.18 | 121.26 | 114.59 | 122.02 | |
Average Inventory |
53.34 | 57.31 | 69.51 | 76.30 | |
Average Assets |
1,072.14 | 1,179.07 | 1,134.53 | 1,119.45 | |
Average Common Equity |
713.81 | 778.20 | 736.37 | 699.39 |
Columns are period end dates